Enterprise Bank & Trust Co Grows Stake in Pfizer Inc. (NYSE:PFE)

Enterprise Bank & Trust Co boosted its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 11.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,135 shares of the biopharmaceutical company’s stock after purchasing an additional 1,550 shares during the quarter. Enterprise Bank & Trust Co’s holdings in Pfizer were worth $776,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. First Citizens Financial Corp increased its holdings in shares of Pfizer by 2.5% in the 4th quarter. First Citizens Financial Corp now owns 11,647 shares of the biopharmaceutical company’s stock valued at $597,000 after acquiring an additional 288 shares during the period. Accurate Wealth Management LLC increased its holdings in shares of Pfizer by 24.4% in the 4th quarter. Accurate Wealth Management LLC now owns 22,850 shares of the biopharmaceutical company’s stock valued at $1,088,000 after acquiring an additional 4,479 shares during the period. Foundations Investment Advisors LLC increased its holdings in shares of Pfizer by 121.3% in the 4th quarter. Foundations Investment Advisors LLC now owns 72,464 shares of the biopharmaceutical company’s stock valued at $3,713,000 after acquiring an additional 39,719 shares during the period. Glassy Mountain Advisors Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at $162,000. Finally, EWG Elevate Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at $134,000. 67.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Berenberg Bank set a $40.00 price target on Pfizer in a report on Tuesday, February 7th. JPMorgan Chase & Co. set a $45.00 price target on Pfizer in a report on Monday, February 27th. SVB Leerink dropped their target price on Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 1st. Atlantic Securities dropped their target price on Pfizer from $50.00 to $46.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 1st. Finally, UBS Group set a $45.00 target price on Pfizer in a research note on Tuesday, March 14th. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $50.38.

Pfizer Stock Performance

Shares of PFE opened at $40.10 on Friday. The stock has a market cap of $225.33 billion, a P/E ratio of 7.32, a P/E/G ratio of 1.35 and a beta of 0.64. The stock has a 50-day moving average of $43.26 and a two-hundred day moving average of $46.03. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22. Pfizer Inc. has a one year low of $39.23 and a one year high of $56.32.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. The business had revenue of $24.30 billion during the quarter, compared to analysts’ expectations of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.08 EPS. As a group, research analysts predict that Pfizer Inc. will post 3.3 EPS for the current year.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.